No Data
No Data
Express News | U.S. Supreme Court Agrees To Hear South Carolina's Bid To End Public Funding Of Abortion Provider Planned Parenthood
HC Wainwright & Co. Reiterates Buy on Dare Bioscience, Maintains $12 Price Target
Daré Bioscience Announces Phase 3 Plans For Sildenafil Cream, 3.6%, In The Treatment Of Female Sexual Arousal Disorder; Daré's Sildenafil Cream Has The Potential To Receive The First FDA Approval For FSAD
Dare Bioscience Announces Publication in Sexual Medicine on RESPOND Study
Express News | Daré Bioscience Announces Publication In Sexual Medicine Highlighting Positive Subgroup Findings From Phase 2b RESPOND Study Of Sildenafil Cream, 3.6%, For Female Sexual Arousal Disorder
Dare Bioscience Received Payment of $2.5M Under Grant Agreement
No Data